The Council of Australian Therapeutic Advisory Groups (CATAG)

CATAG is an authoritative, expert, consensus-based collaboration of representatives from all Australian State and Territory Therapeutic Advisory Groups or their jurisdictional committee equivalents. CATAG aims to standardise and improve medicines use primarily (but not exclusively) in the hospital sector across Australia through:

For more information about CATAG visit the about section.

Updates

Navigating high-cost medicines. Guiding principles for the governance of high-cost medicines in Australian hospitals, Version 1 January 2022
The purpose of these Guiding Principles is to provide a principles based high level framework outlining national objectives to assist medicines governance committees, including Drugs and Therapeutics Committees (DTCs), to assess and make good decisions about the quality use of high‑cost medicines. In addition, a recommendation for the future management of high-cost medicines by jurisdictions, area health service and local hospital and health service organisations has been made. 
CATAG Navigating high-cost medicines

Biologics and biosimilars best practice: Guiding principles for the governance of biologics in Australian public hospitals, Version 3 2021
CATAG Biologics and biosimilars best practice
Appendix 2: Biosimilar medicines switch communication templates
Checklist for governance of biologics and their biosimilars

Optimising My Health Record utilisation: CATAG Position statement on the use of My Health Record by Australian public hospitals
The Position statement is to support the use of the My Health Record (MHR) in Australia public hospitals as a tool to facilitate shared decision making, optimise the quality use of medicines, facilitate medicines-related communications to ensure continuity of pharmaceutical care and reduce preventable medication-related harm including unplanned re-hospitalisation.
CATAG Position Statement My Health Record

Making safe and wise decisions about biological disease-modifying anti rheumatic drugs (bDMARDs) and other specialised medicines
A consortium of health organisations has been awarded a grant under the Australian Government’s Value in Prescribing program bDMARDs stream. A range of interventions have been developed by the consortium partners, as part of the program CATAG has developed a position statement on the use of low dose methotrexate.
CATAG Position Statement on the use of low-dose methotrexate
Checklist for governance of low-dose methotrexate in hospitals

Facilitating the translation of evidence into best practice:
Optimising the pharmacological management of inflammatory arthritis 
CATAG has developed this document to facilitate and support the translation of best available evidence into practice for the management of inflammatory arthritis. 
CATAG optimising the pharmacological management of inflammatory arthritis March 2022

Facilitating the translation of evidence into best practice: Therapeutic drug monitoring in inflammatory bowel disease
CATAG Therapeutic drug monitoring in inflammatory bowel disease

ViP bDMARDs Stakeholder report: CATAG activities and recommendations.

This report describes the results of a survey to gain an understanding of current formulary and individual patient use (IPU)/ individual patient approval (IPA) activities and QUM issues with regards to the use of biologicals and biosimilars in hospital and health services, which then informed the development of CATAG resources as part of the ViP bDMARDs program.

Leave a Reply

© Copyright 2012 The Council of Australian Therapeutic Advisory Groups
Disclaimer | Copyright Policy